This segment focuses on the development and commercialization of therapies for Renal Cell Carcinoma (RCC), a type of kidney cancer. The primary product in this segment is FOTIVDA (tivozanib), an oral, once-daily vascular endothelial growth factor receptor tyrosine kinase inhibitor. Research and development activities include clinical trials to evaluate FOTIVDA in various settings, including combination therapies. The company is also exploring tivozanib for other indications, such as hepatocellular carcinoma (HCC). The patient impact is significant, as FOTIVDA provides a treatment option for patients with advanced RCC. Market positioning is strengthened by the FDA approval of FOTIVDA. Future opportunities include expanding the use of FOTIVDA and developing new therapies for RCC. Regulatory aspects involve ongoing interactions with regulatory bodies like the FDA. Partnerships with other pharmaceutical companies are crucial for clinical trials and commercialization.

This segment encompasses the broader research and development efforts focused on discovering and developing novel cancer therapies. AVEO utilizes its expertise in cancer biology to identify and advance promising drug candidates. This includes the development of Ficlatuzumab, a humanized monoclonal antibody targeting hepatocyte growth factor, and AV-380, a monoclonal antibody for cachexia. The company employs various technologies, including antibody engineering and clinical trial design, to advance its pipeline. Therapeutic areas include squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia. The goal is to improve patient outcomes and provide new treatment options for various cancers. Market positioning is enhanced through strategic partnerships and collaborations. Future opportunities involve expanding the pipeline and exploring new therapeutic targets. Regulatory aspects include navigating the drug approval process with regulatory agencies. Partnerships with companies like Eli Lilly and Company are essential for clinical trials and commercialization.